bearish

Resapp Health

ResApp’s Scheme Meeting on 7 September Still Faces Headcount Test Risk

The headcount test remains a key risk. The upside (9.5% spread to the offer) vs downside (likely equity raise at a huge discount) is an unfavourable risk/reward profile.

Event-Driven
188 Views, 29 Aug 2022 20:46
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top 5%
Arun George
IPOs and Catalysts/Events
Global Equity Research Ltd
Information TechnologyEquitiesEquity Capital MarketsEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • ResApp’s Scheme Meeting on 7 September Still Faces Headcount Test Risk
    29 Aug 2022
  • ResApp’s Revised Offer from Pfizer Still Faces Headcount Test Risk
    04 Aug 2022
  • ResApp’s Confirmatory Study Fails, Resulting in Pfizer’s Lower A$0.146 Offer
    21 Jun 2022
  • ResApp Draws a Revised Binding Offer from Pfizer
    14 Jun 2022
x